A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.

Trial Profile

A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENESTFreedom
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2018 Results presenting a long-term (144-wk) analysis of the durability and safety of treatment free remission presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results assessing efficacy of nilotinib (Data cutoff: Oct 11, 2017, 144 week) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2018 Results presented in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top